NCT06648512View on ClinicalTrials.gov

Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

March 7, 2025

Study Completion Date

March 7, 2025

Conditions

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) Relapse

Interventions

OTHER

No Interventions

No Intervention

Trial Locations (3)

8010

Medizinische Universität Graz, Graz

12203

Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie und Onkologie, Berlin

01730

FHRB (Finnish Hematology Registry and Clinical Biobank), Vantaa

All Listed Sponsors

lead

Exscientia AI Limited

INDUSTRY

NCT06648512 - Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2) | Biotech Hunter | Biotech Hunter